BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Musolino A, Boggiani D, Pellegrino B, Zanoni D, Sikokis A, Missale G, Silini EM, Maglietta G, Frassoldati A, Michiara M. Role of innate and adaptive immunity in the efficacy of anti-HER2 monoclonal antibodies for HER2-positive breast cancer. Crit Rev Oncol Hematol 2020;149:102927. [PMID: 32172224 DOI: 10.1016/j.critrevonc.2020.102927] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Golay J, Taylor RP. The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer mAbs. Antibodies (Basel) 2020;9:E58. [PMID: 33126570 DOI: 10.3390/antib9040058] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
2 Henriques B, Mendes F, Martins D. Immunotherapy in Breast Cancer: When, How, and What Challenges? Biomedicines 2021;9:1687. [PMID: 34829916 DOI: 10.3390/biomedicines9111687] [Reference Citation Analysis]
3 Rugo HS, Im SA, Cardoso F, Cortés J, Curigliano G, Musolino A, Pegram MD, Wright GS, Saura C, Escrivá-de-Romaní S, De Laurentiis M, Levy C, Brown-Glaberman U, Ferrero JM, de Boer M, Kim SB, Petráková K, Yardley DA, Freedman O, Jakobsen EH, Kaufman B, Yerushalmi R, Fasching PA, Nordstrom JL, Bonvini E, Koenig S, Edlich S, Hong S, Rock EP, Gradishar WJ; SOPHIA Study Group. Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol 2021;7:573-84. [PMID: 33480963 DOI: 10.1001/jamaoncol.2020.7932] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 23.0] [Reference Citation Analysis]
4 Mandó P, Rivero SG, Rizzo MM, Pinkasz M, Levy EM. Targeting ADCC: A different approach to HER2 breast cancer in the immunotherapy era. Breast 2021;60:15-25. [PMID: 34454323 DOI: 10.1016/j.breast.2021.08.007] [Reference Citation Analysis]
5 Dieci MV, Miglietta F, Griguolo G, Guarneri V. Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors. Cancer Treat Rev 2020;88:102064. [PMID: 32622272 DOI: 10.1016/j.ctrv.2020.102064] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
6 Musolino A, Gradishar WJ, Rugo HS, Nordstrom JL, Rock EP, Arnaldez F, Pegram MD. Role of Fcγ receptors in HER2-targeted breast cancer therapy. J Immunother Cancer 2022;10:e003171. [PMID: 34992090 DOI: 10.1136/jitc-2021-003171] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]